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Abstract 
 
To evaluate the association of ATP binding cassette subfamily-B member-1 (ABCB1) genetic 
variants with the susceptibility to Alzheimer’s disease (AD), we genotyped the rs1128503 
(C1236T), rs2032582 (G2677T/A) and rs1045642 (C3435T) polymorphisms in a case-control 
sample (234 AD patients, 225 controls). Single-marker analyses revealed significant 
association solely for rs1045642 polymorphism (C/C genotype carriers had increased risk for 
AD), which remains significant after correction for multiple testing. Haplotype analyses 
indicated three nominally significant associations which were lost after applying multiple test 
correction. 
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Background 
 
Late-onset Alzheimer’s disease (AD), the most common cause of dementia, is a complex 
neurodegenerative disorder with a strong genetic predisposition; however, in spite of the 
extensive research, the larger part of its heritable background is still an open question. At the 
molecular level, accumulation and aggregation of the amyloid-β (Aβ) peptides, leading to 
senile plaque formation; and hyperphosphorylation of the tau protein, resulting in 
neurofibrillary tangle generation, are the major features of AD pathology. 
 Adenosine-triphosphate (ATP) binding cassette subfamily B member 1 gene (ABCB1; 
MIM# 171050) at locus 7q21.1 encodes P-glycoprotein (P-gp), an efflux transporter that is 
located at the luminal side of the cerebral endothelial cells at the blood brain barrier (Pahnke 
et al., 2008). P-gp effectively prevents a number of structurally different drugs and toxicants 
from entering the brain and removes metabolic waste products from the brain, hence P-gp has 
an essential role in neuroprotection and overall brain homeostasis (Wolf et al., 2012). With 
respect to AD, the involvement of P-gp in Aβ transport is particularly important. Compared to 
healthy controls, Aβ clearance from the brain is significantly decreased in AD patients 
(Mawuenyega et al., 2010).  
 In vitro experiments provided evidence that P-gp is capable of transporting Aβ (Lam 
et al., 2001; Kuhnke et al., 2007), and consistent with these findings, reduced P-gp activity via 
inhibition or genetic modification was reported to reduce Aβ clearance from the brain in an 
AD mouse model (Cirrito et al., 2005). Additionally, the link between P-gp and AD is also 
supported by results on the inverse correlation between cerebral Aβ deposition and vascular 
P-gp expression at the blood brain barrier (Vogelgesang et al., 2002; Jeynes and Provias, 
2011). 
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 The ABCB1 gene is highly polymorphic. The rs1128503 single nucleotide 
polymorphism (SNP) is a nucleotide change in exon 12 (C1236T) that does not alter the 
Glycine at position 412. The tri-allelic rs2032582 polymorphism in exon 21 (G2677T/A) 
leads to an Alanine to Threonine or Serine amino acid substitution (Ala893Thr/Ser). The 
rs1045642 synonymous polymorphism in exon 26 (C3435T) does not affect the Ileucine at 
position 1145. To evaluate the possible association of ABCB1 genetic variations with the 
susceptibility to late-onset AD, we performed a case-control study of a Hungarian sample 
genotyping the rs1128503, rs2032582 and rs1045642 polymorphisms. 
 
 
Subjects and methods 
 
A total of 234 Hungarian patients with late-onset AD (age: 75.6 ± 6.8 years (mean ± SD), 
men: 32.1%) and 225 Hungarian, elderly, cognitively intact, healthy controls (age: 74.8 ± 7.2 
years (mean ± SD), men: 33.3%) were involved in the study. The AD patients were recruited 
from the Memory Clinic of the Department of Psychiatry, University of Szeged. A consensus 
clinical diagnosis of probable late-onset AD was established according to the National 
Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and 
Related Disorders Association (NINCDS/ADRDA) criteria (McKhann et al., 1984). The 
minimum age at onset was 65 years. Global cognitive performance was measured by the 
Mini-Mental State Examination (MMSE). The mean MMSE score in the AD group was 17.3 
± 5.7 (mean ± SD), while in the control group MMSE scores were higher than 28 points and 
none of the control probands had any verified symptoms of dementia. All recruitment and 
protocols were conducted with written informed consent and with the explicit approval of the 
Ethics Committee of the Hungarian Council on Science and Health (ETT-TUKEB). 
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 Genomic DNA was extracted from peripheral blood leukocytes using standard 
procedures. The investigated polymorphisms were genotyped using the method of PCR and 
enzyme digestion (PCR-RFLP). ABCB1 rs1128503 genotypes were determined by a formerly 
described procedure with the restriction enzyme BsuRI (Sipeky et al., 2011). Genotyping of 
the ABCB1 rs2032582 polymorphism was carried out as previously described with the 
restriction enzymes BseYI and RsaI (Cascorbi et al., 2004). Genotyping of the ABCB1 
rs1045642 polymorphism was assessed by the same method described by Cascorbi et al. 
(2004) with the restriction enzyme MboI. 
 Genotype and allele frequencies were compared between patients and controls using 
Pearson’s chi square and Fisher’s exact tests. To exclude Type I errors, Bonferroni’s 
correction for multiple testing was applied for 3 single-marker and 8 haplotype comparisons. 
The gender distribution of the AD and control groups was compared with Fisher’s exact and 
the mean age was compared by using the t-test for independent samples. No statistically 
significant difference was found in the distribution of genders or in mean age between AD 
and control groups (p>0.05). Hardy–Weinberg Equilibrium (HWE) testing, linkage 
disequilibrium (LD) calculations and haplotype analyses were conducted using Haploview 4.2 
(Barrett et al., 2005). Power analysis was performed using GPower 3.0 software (Faul et al., 
2007) and the effect size was determined according to the method published by Cohen, 1988. 
Our study sample (n=459) has 81% power at the significance level of 0.05 to detect 
differences in rs1045642 genotypes between AD patients and controls (effect size: w=0.146). 
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Results 
 
Genotype frequencies of the investigated polymorphisms in the AD and control groups 
applied to HWE (p>0.05). LD and haplotype data were inferred from genotype data only for 
subjects not carrying the rs2032582 A allele because of its very low occurrence in both AD 
and control groups. Table 1 presents the LD characteristics of the genotyped polymorphisms. 
Moderate LD was observed between rs1128503 and rs2032582 (D’=0.749, r2=0.434), and 
between rs2032582 and rs1045642 polymorphisms (D’=0.729, r2=0.376), and weak LD was 
detected between rs1128503 and rs1045642 polymorphisms (D’=0.474, r2=0.203). 
 The genotype and haplotype frequencies of the ABCB1 polymorphisms are 
summarized in Table 2. The ratio of the different rs1128503 genotypes was similar in the AD 
and in the control groups, and showed no statistically significant difference (χ2=0.506 (2) 
p=0.776). Regarding the rs2032582 polymorphism, no A/A genotype carriers were found, 
besides, the G/A and the T/A genotypes had a very low frequency in both investigated groups. 
The G/G and G/T genotypes occurred at a slightly higher frequency in the AD than in the 
control group; however, the difference was not statistically significant (χ2=3.951 (4) p=0.413). 
Compared with the controls, the rs1045642 C/C genotype was significantly over-represented 
in the AD group (χ2=9.840 (2) p=0.007, corrected: p=0.021). The C/C genotype carriers had a 
significantly increased risk for AD (OR=2.29, 95%CI: 1.35-3.88, p=0.002) considering the 
T/T genotype carriers as reference category. 
 The predominant haplotypes of the markers rs1128503, rs2032582 and rs1045642 
were the C-G-C and T-T-T in both AD and control groups. Our haplotype analyses revealed 
three nominally significant associations (Table 2). The T-T-T and T-T-C haplotypes were 
more frequent in the control group than in the AD group (T-T-T: p=0.040; corrected p=0.320; 
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T-T-C: p=0.016; corrected p=0.128), while the C-T-T haplotype had a higher occurrence in 
the AD group (p=0.032; corrected p=0.256). 
 
 
Discussion 
 
In single-marker case–control analyses, we found a significant association only for rs1045642 
polymorphism out of the three investigated SNPs. Even after correcting p values using the 
Bonferroni’s method for multiple tests, this significant correlation was still found. 
Significantly increased susceptibility to AD associated with rs1045642 C/C genotype was 
found considering T/T genotype as the reference category. The genotype distributions of the 
rs1128503 and rs2032582 polymorphisms were similar in the AD and control groups without 
a statistically significant difference.  
 Even though the synonymous rs1045642 polymorphism does not produce altered 
coding sequence, it seems to have functional consequences, since it was reported to result in 
lower intestinal P-gp expression and increased oral bioavailability of the Pgp substrate 
digoxin, decreased mRNA stability and expression, and reduced protein function (Hoffmeyer 
et al., 2000; Wang et al., 2005; Assema et al., 2012). On the other hand, reports of conflicting 
results can also be found (Sakaeda et al., 2001; Nakamura et al., 2002). 
 The frequencies of the investigated ABCB1 genotypes in our control sample are 
comparable to earlier reports on other control populations of Caucasian origin (Cascorbi et al., 
2004; Sipeky et al., 2011). Two case-control studies with small and medium sample size 
reported no association between rs2032582 or rs1045642 polymorphism and the risk for AD 
(Frankfort et al., 2006; Kohen et al., 2011), and two genome wide association studies also did 
not detect correlation between rs1045642 polymorphism and the genetic susceptibility to AD 
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(Reiman et al., 2007; Li et al., 2008). The ABCB1 polymorphisms were also studied in a 
histopathologically confirmed AD case-control sample and no effect of ABCB1 variants was 
found in the entire cohort; however, a significant association was detected between rs2032582 
genotypes and AD risk among females and individuals older than 65 years (Cascorbi et al., 
2013).  
 Frankfort and co-workers showed evidence for the correlation between ABCB1 
rs1128503 and rs2032582 genotypes and Aβ serum profile, and therefore suggested further 
research on the potential involvement of ABCB1 genetic variations in AD (Frankfort et al., 
2008). Another investigation revealed significant differences in peripheral leukocyte gene 
expression profiles between AD patients and non-demented controls, and found that ABCB1 
gene had decreased expression in AD and the ABCB1 expression levels were positively 
correlated with MMSE score (Chen et al., 2011). 
 The investigated polymorphisms are not strictly allelic, they showed LD, hence we 
also performed the haplotype estimation between cases and controls, and found moderate 
(between rs1128503 and rs2032582, and between rs2032582 and rs1045642 polymorphisms) 
and weak LD (between rs1128503 and rs1045642 polymorphisms) in our sample. Consistent 
with findings of previous studies, the C-G-C and T-T-T were the predominant haplotypes of 
the rs1128503, rs2032582, and rs1045642 polymorphisms in both investigated groups. 
Haplotype analyses revealed three nominally significant associations for T-T-T, T-T-C and C-
T-T haplotypes, however, they did not remain significant after applying the Bonferroni’s 
correction for multiple tests. 
 The present study led to the conclusion that ABCB1 rs1045642 polymorphism may 
have a role in the genetic risk for developing AD. Subjects carrying the C/C genotype of 
ABCB1 gene appeared to exhibit AD significantly more frequently. The medium size of our 
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sample, an important limitation, should be mentioned, and further investigations with 
considerably larger samples and in detail using more markers are required. 
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Table 1. Linkage disequilibrium characteristics of the investigated ABCB1 polymorphisms 
Polymorphisms MAF (%) p value        Linkage disequilibrium 
  AD patients Controls  with D’ r2 
rs1128503 1236C>T 48.3% 49.6% 0.702 rs2032582 0.749 0.434 
rs2032582# 2677G>T 41.2% 45.8% 0.170 rs1045642 0.729 0.376 
rs1045642 3435C>T 46.4% 56.7% 0.002** rs1128503 0.474 0.203 
ABCB1: ATP binding cassette subfamily B member 1; MAF: minor allele frequency; AD: Alzheimer’s disease 
#Linkage disequilibrium data were inferred from genotype data only for subjects not carrying the A allele of the 
rs2032582 polymorphism. 
 
 
Table 2. Genotype and haplotype frequencies of the investigated ABCB1 polymorphisms 
 AD patients 
 
Controls 
 
chi square p value 
rs1128503   0.506 0.776 
   C/C 56 (23.9%) 54 (24.0%)   
   C/T 130 (55.6%) 119 (52.9%)   
   T/T 48 (20.5%) 52 (23.1%)   
rs2032582   3.951 0.413 
   G/G 69 (29.5%) 62 (27.6%)   
   G/T 123 (52.6%) 109 (48.4%)   
   T/T 30 (12.8%) 44 (19.6%)   
   G/A 9 (3.8%) 8 (3.5%)   
   T/A 3 (1.3%) 2 (0.9%)   
   A/A ND ND   
rs1045642   9.840 0.007** 
   C/C 66 (28.2%) 43 (19.1%)   
   C/T 119 (50.9%) 109 (48.4%)   
   T/T 49 (20.9%) 73 (32.5%)   
Haplotypes#     
   C-G-C 172 (36.9%) 146 (32.4%) 2.008 0.157 
   T-T-T 141 (30.1%) 164 (36.5%) 4.227 0.040* 
   C-G-T 46 (9.8%) 54 (11.9%) 1.070 0.301 
   T-G-C 41 (8.8%) 35 (7.7%) 0.384 0.536 
   T-T-C 25 (5.4%) 10 (2.3%) 5.780 0.016* 
   C-T-T 12 (2.5%) 23 (5.2%) 4.582 0.032* 
   T-G-T 19 (4.0%) 14 (3.1%) 0.575 0.448 
   C-T-C 12 (2.5%) 4 (0.9%) 3.625 0.057 
ABCB1: ATP binding cassette subfamily B member 1; AD: Alzheimer’s disease; ND: not detected 
#Haplotypes of the rs1128503, rs2032582 and rs1045642 polymorphisms. Haplotype data were inferred from 
genotype data only for subjects not carrying the A allele of the rs2032582 polymorphism. Chi squares and p 
values for comparisons of the haplotype frequencies were determined by using the Haploview 4.2 program. 
 
 
 
 
